You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

What Is the Expert Accord on Identifying and Protecting the Patient at Early Stage of CKD?

  • Authors: Lawrence Leiter, MD, FRCPC, FACP, FACE FAHA, FACC; Per-Henrik Groop, MD, DMSc, FRCPE; Radica Alicic, MD, MS, FACP, FHM
  • CPD Released: 3/14/2023
  • Valid for credit through: 3/14/2024
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, diabetologists/endocrinologists, and nephrologists.

The goal of this activity is for learners to be better able to recognize the importance of early chronic kidney disease (CKD) detection, not only in patients with diabetes, as well as the benefits and practical use of reno-protective therapies like sodium-glucose cotransporter 2 (SGLT2) inhibitors in CKD management.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Urgent need for the early identification of patients with CKD
    • Latest results of CKD outcomes trials with reno-protective drugs
  • Have greater competence related to
    • The practical use of SGLT2 inhibitors with proven kidney benefit in a broad range of patients with CKD


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Lawrence Leiter, MD, FRCPC, FACP, FACE FAHA, FACC

    Professor of Medicine and Nutritional Sciences
    University of Toronto
    Division of Endocrinology and Metabolism
    St. Michael's Hospital
    Toronto, Ontario, Canada

    Disclosures

    Lawrence Leiter, MD, FRCPC, FACP, FACE FAHA, FACC , has the following relevant financial relationships: 
    Consultant or advisor for: Abbott; Amarin Corporation plc; Amgen Inc.; AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; HLS Therapeutics; Merck; Novartis; Novo Nordisk; Pfizer Inc.; Sanofi
    Speaker or member of speakers bureau for: Amarin Corporation plc; Amgen Inc.; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; HLS Therapeutics; Novartis; Novo Nordisk; Pfizer Inc.; SERVIER
    Research funding from: Amgen Inc.; AstraZeneca; Bayer; Kowa Company Ltd.; Novartis    
    Other: Member of DSMB for Applied Therapeutics

Faculty

  • Per-Henrik Groop, MD, DMSc, FRCPE

    Professor of Internal Medicine (chair)
    University of Helsinki
    Chief Physician 
    Helsinki University Hospital
    Helsinki, Finland

    Disclosures

    Per-Henrik Groop, MD, DMSc, FRCPE, has the following relevant financial relationships: 
    Consultant or advisor for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Merck Sharp & Dohme; Nestlè; Novo Nordisk
    Speaker or member of speakers bureau for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme; SCIARC

  • Radica Alicic, MD, MS, FACP, FHM

    Clinical Professor
    Department of Medicine
    University of Washington School of Medicine
    Providence Medical Research Center
    Providence Health Care
    Spokane and Seattle, Washington, United States

    Disclosures

    Radica Alicic, MD, MS, FACP, FHM, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.
    Research funding from: Bayer (former)

Editor

  • Rita Moreira Da Silva, PhD, MA, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

What Is the Expert Accord on Identifying and Protecting the Patient at Early Stage of CKD?

Authors: Lawrence Leiter, MD, FRCPC, FACP, FACE FAHA, FACC; Per-Henrik Groop, MD, DMSc, FRCPE; Radica Alicic, MD, MS, FACP, FHMFaculty and Disclosures

CPD Released: 3/14/2023

Valid for credit through: 3/14/2024

processing....

Transcription en français

Download the pdf.

« Return to: What Is the Expert Accord on Identifying and Protecting the Patient at Early Stage of CKD?
  • Print